Profile data is unavailable for this security.
About the company
AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
- Revenue in EUR (TTM)1.08m
- Net income in EUR-6.04m
- Incorporated2001
- Employees45.00
- LocationAB Science SA3 avenue George VPARIS 75008FranceFRA
- Phone+33 147200014
- Fax+33 147202411
- Websitehttps://www.ab-science.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valerio Therapeutics SA | 1.89m | -19.66m | 12.35m | 38.00 | -- | 3.06 | -- | 6.54 | -0.1233 | -0.1233 | 0.0119 | 0.0261 | 0.0515 | -- | 0.5121 | 99,421.05 | -53.59 | -34.19 | -76.22 | -40.59 | 74.75 | 84.11 | -1,040.66 | -586.99 | -- | -188.64 | 0.7662 | -- | 24.74 | -21.73 | -4.00 | -- | 32.39 | -- |
| SMAIO SA | 4.91m | -1.79m | 14.17m | 43.00 | -- | 1.76 | -- | 2.88 | -0.3383 | -0.3383 | 0.929 | 1.54 | 0.3738 | 0.3816 | 9.41 | 132,756.80 | -13.65 | -7.87 | -15.68 | -18.43 | 88.45 | 96.04 | -36.52 | -22.48 | 4.25 | -- | 0.236 | -- | 212.18 | 114.99 | -62.80 | -- | -- | -- |
| NicOx SA | -100.00bn | -100.00bn | 15.74m | 5.00 | -- | 0.7203 | -- | -- | -- | -- | -- | 0.3166 | -- | -- | -- | -- | -- | -22.59 | -- | -24.55 | -- | -- | -- | -337.85 | -- | -- | 0.5424 | -- | 26.59 | 11.38 | 33.26 | -- | -- | -- |
| Advicenne SA | 3.02m | -8.83m | 26.00m | 20.00 | -- | -- | -- | 8.61 | -0.7538 | -0.7538 | 0.2608 | -1.42 | 0.3234 | 3.85 | 1.87 | 150,950.00 | -94.59 | -57.86 | -- | -89.10 | -116.10 | -327.56 | -292.51 | -513.56 | 0.2611 | -22.23 | 156.51 | -- | 25.67 | 25.03 | 38.70 | -- | 55.28 | -- |
| Aelis Farma SA | 7.55m | -7.03m | 41.12m | 26.00 | -- | 4.00 | -- | 5.44 | -0.5319 | -0.5319 | 0.5717 | 0.75 | 0.2779 | -- | 1.56 | 290,461.50 | -25.85 | -24.53 | -40.55 | -40.55 | -- | -- | -93.03 | -109.62 | 2.97 | -- | 0.277 | -- | 137.70 | -- | 64.46 | -- | 37.35 | -- |
| AB Science SA | 1.08m | -6.04m | 51.53m | 45.00 | -- | -- | -- | 47.62 | -0.1204 | -0.1204 | 0.0213 | -0.4697 | 0.0385 | 0.6465 | 6.98 | 20,415.09 | -21.51 | -65.95 | -70.06 | -515.17 | 76.25 | 88.41 | -558.50 | -1,148.98 | 0.798 | -9.11 | -- | -- | 1.25 | -10.63 | 11.97 | -- | -6.55 | -- |
| Groupe Berkem SA | 52.43m | -1.42m | 54.37m | 200.00 | -- | -- | 15.99 | 1.04 | -0.0799 | -0.0799 | 2.95 | -- | -- | -- | -- | 262,130.00 | -- | -- | -- | -- | 56.41 | -- | -2.71 | -- | -- | 0.1565 | -- | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| DBV Technologies SA | 13.12m | -83.97m | 60.02m | 106.00 | -- | 0.7963 | -- | 4.58 | -0.8733 | -0.8733 | 0.1365 | 0.781 | 0.0833 | -- | 0.7321 | 126,141.70 | -53.33 | -53.18 | -65.29 | -65.47 | -- | 93.62 | -640.08 | -1,145.92 | -- | -- | 0.083 | -- | 224.69 | -1.71 | 24.27 | -- | -34.47 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Financi�re Arbevel SAas of 30 Dec 2022 | 138.62k | 0.27% |
| State of Wisconsin Investment Boardas of 31 Dec 2022 | 3.86k | 0.01% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2023 | 3.56k | 0.01% |
| Ursus-3 Capital, AV, SAas of 30 Jun 2024 | 3.10k | 0.01% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 707.00 | 0.00% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2023 | 0.00 | 0.00% |
| Allianz Polska PTE SAas of 28 Jun 2024 | 0.00 | 0.00% |
| Mercer Global Investments Europe Ltd.as of 31 Dec 2023 | 0.00 | 0.00% |
| La Fran�aise Asset Management SASas of 31 Jul 2024 | 0.00 | 0.00% |
